Shyam D Rao1,2, Ziad H Saleh3, Jeremy Setton2, Moses Tam2, Sean M McBride2, Nadeem Riaz2, Joseph O Deasy3, Nancy Y Lee2. 1. a Department of Radiation Oncology , University of California Davis Comprehensive Cancer Center , Sacramento , California , USA. 2. b Department of Radiation Oncology , Memorial Sloan Kettering Cancer Center , New York , New York , USA. 3. c Department of Medical Physics , Memorial Sloan Kettering Cancer Center , New York , New York , USA.
Abstract
BACKGROUND: To investigate the dose-volume factors in mastication muscles that are implicated as possible causes of trismus in patients following treatment with intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy for head and neck cancers. MATERIAL AND METHODS: All evaluable patients treated at our institution between January 2004 and April 2009 with chemotherapy and IMRT for squamous cell cancers of the oropharynx, nasopharynx, hypopharynx or larynx were included in this analysis (N = 421). Trismus was assessed using CTCAE 4.0. Bi-lateral masseter, temporalis, lateral pterygoid and medial pterygoid muscles were delineated on axial computed tomography (CT) treatment planning images, and dose-volume parameters were extracted to investigate univariate and multimetric correlations. RESULTS: Forty-six patients (10.9%) were observed to have chronic trismus of grade 1 or greater. From analysis of baseline patient characteristics, toxicity correlated with primary site and patient age. From dose-volume analysis, the steepest dose thresholds and highest correlations were seen for mean dose to ipsilateral masseter (Spearman's rank correlation coefficient Rs = 0.25) and medial pterygoid (Rs = 0.23) muscles. Lyman-Kutcher-Burman modeling showed highest correlations for the same muscles. The best correlation for multimetric logistic regression modeling was with V68Gy to the ipsilateral medial pterygoid (Rs = 0.29). CONCLUSION: Chemoradiation-induced trismus remains a problem particularly for patients with oropharyngeal carcinoma. Strong dose-volume correlations support the hypothesis that limiting dose to the ipsilateral masseter muscle and, in particular, the medial pterygoid muscle may reduce the likelihood of trismus.
BACKGROUND: To investigate the dose-volume factors in mastication muscles that are implicated as possible causes of trismus in patients following treatment with intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy for head and neck cancers. MATERIAL AND METHODS: All evaluable patients treated at our institution between January 2004 and April 2009 with chemotherapy and IMRT for squamous cell cancers of the oropharynx, nasopharynx, hypopharynx or larynx were included in this analysis (N = 421). Trismus was assessed using CTCAE 4.0. Bi-lateral masseter, temporalis, lateral pterygoid and medial pterygoid muscles were delineated on axial computed tomography (CT) treatment planning images, and dose-volume parameters were extracted to investigate univariate and multimetric correlations. RESULTS: Forty-six patients (10.9%) were observed to have chronic trismus of grade 1 or greater. From analysis of baseline patient characteristics, toxicity correlated with primary site and patient age. From dose-volume analysis, the steepest dose thresholds and highest correlations were seen for mean dose to ipsilateral masseter (Spearman's rank correlation coefficient Rs = 0.25) and medial pterygoid (Rs = 0.23) muscles. Lyman-Kutcher-Burman modeling showed highest correlations for the same muscles. The best correlation for multimetric logistic regression modeling was with V68Gy to the ipsilateral medial pterygoid (Rs = 0.29). CONCLUSION: Chemoradiation-induced trismus remains a problem particularly for patients with oropharyngeal carcinoma. Strong dose-volume correlations support the hypothesis that limiting dose to the ipsilateral masseter muscle and, in particular, the medial pterygoid muscle may reduce the likelihood of trismus.
Authors: I El Naqa; G Suneja; P E Lindsay; A J Hope; J R Alaly; M Vicic; J D Bradley; A Apte; J O Deasy Journal: Phys Med Biol Date: 2006-10-19 Impact factor: 3.609
Authors: M Louise Kent; Michael T Brennan; Jenene L Noll; Philip C Fox; Stuart H Burri; Jane C Hunter; Peter B Lockhart Journal: Support Care Cancer Date: 2007-10-27 Impact factor: 3.603
Authors: David N Teguh; Peter C Levendag; Peter Voet; Henri van der Est; Inge Noever; Willy de Kruijf; Peter van Rooij; Paul I M Schmitz; Ben J Heijmen Journal: Head Neck Date: 2008-05 Impact factor: 3.147
Authors: Adepitan A Owosho; SaeHee K Yom; Zhiqiang Han; Kevin Sine; Nancy Y Lee; Joseph M Huryn; Cherry L Estilo Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2016-07-19
Authors: Adepitan A Owosho; Luciana M Pedreira Ramalho; Haley I Rosenberg; SaeHee K Yom; Esther Drill; Elyn Riedel; C Jillian Tsai; Nancy Y Lee; Joseph M Huryn; Cherry L Estilo Journal: J Craniomaxillofac Surg Date: 2016-06-16 Impact factor: 2.078
Authors: Aditi Iyer; Maria Thor; Ifeanyirochukwu Onochie; Jennifer Hesse; Kaveh Zakeri; Eve LoCastro; Jue Jiang; Harini Veeraraghavan; Sharif Elguindi; Nancy Y Lee; Joseph O Deasy; Aditya P Apte Journal: Phys Med Biol Date: 2022-01-17 Impact factor: 3.609
Authors: Maria Thor; Aditi Iyer; Jue Jiang; Aditya Apte; Harini Veeraraghavan; Natasha B Allgood; Jennifer A Kouri; Ying Zhou; Eve LoCastro; Sharif Elguindi; Linda Hong; Margie Hunt; Laura Cerviño; Michalis Aristophanous; Masoud Zarepisheh; Joseph O Deasy Journal: Phys Imaging Radiat Oncol Date: 2021-07-28
Authors: Wen Chen; Yimin Li; Brandon A Dyer; Xue Feng; Shyam Rao; Stanley H Benedict; Quan Chen; Yi Rong Journal: Radiat Oncol Date: 2020-07-20 Impact factor: 3.481
Authors: Xiangguo Zhang; Haihui Chen; Wen Chen; Brandon A Dyer; Quan Chen; Stanley H Benedict; Shyam Rao; Yi Rong Journal: J Appl Clin Med Phys Date: 2020-08-25 Impact factor: 2.102